Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects
This study has been completed.
Information provided by:
First received: October 17, 2006
Last updated: August 16, 2010
Last verified: August 2010
The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients|
Resource links provided by NLM:
Further study details as provided by ALK-Abelló A/S:
Primary Outcome Measures:
- Use of inhaled corticosteroid (ICS).
Secondary Outcome Measures:
- Use of rescue medication and symptoms.
- Quality of Life.
|Study Start Date:||August 2006|
|Study Completion Date:||April 2008|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Contacts and Locations